View Item 

Show simple item record

Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 Omicron variant, US Flu VE network
dc.contributor.authorTartof, Sara Y.
dc.contributor.authorXie, Fagen
dc.contributor.authorYadav, Ruchi
dc.contributor.authorWernli, Karen J.
dc.contributor.authorMartin, Emily T.
dc.contributor.authorBelongia, Edward A.
dc.contributor.authorGaglani, Manjusha
dc.contributor.authorZimmerman, Richard K.
dc.contributor.authorTalbot, H. Keipp
dc.contributor.authorThornburg, Natalie
dc.contributor.authorFlannery, Brendan
dc.date.accessioned2023-06-01T20:51:57Z
dc.date.available2024-06-01 16:51:55en
dc.date.available2023-06-01T20:51:57Z
dc.date.issued2023-05
dc.identifier.citationTartof, Sara Y.; Xie, Fagen; Yadav, Ruchi; Wernli, Karen J.; Martin, Emily T.; Belongia, Edward A.; Gaglani, Manjusha; Zimmerman, Richard K.; Talbot, H. Keipp; Thornburg, Natalie; Flannery, Brendan (2023). "Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 Omicron variant, US Flu VE network." Influenza and Other Respiratory Viruses 17(5): n/a-n/a.
dc.identifier.issn1750-2640
dc.identifier.issn1750-2659
dc.identifier.urihttps://hdl.handle.net/2027.42/176890
dc.description.abstractBackgroundWe estimated combined protection conferred by prior SARS-CoV-2 infection and COVID-19 vaccination against COVID-19-associated acute respiratory illness (ARI).MethodsDuring SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant circulation between October 2021 and April 2022, prospectively enrolled adult patients with outpatient ARI had respiratory and filter paper blood specimens collected for SARS-CoV-2 molecular testing and serology. Dried blood spots were tested for immunoglobulin-G antibodies against SARS-CoV-2 nucleocapsid (NP) and spike protein receptor binding domain antigen using a validated multiplex bead assay. Evidence of prior SARS-CoV-2 infection also included documented or self-reported laboratory-confirmed COVID-19. We used documented COVID-19 vaccination status to estimate vaccine effectiveness (VE) by multivariable logistic regression by prior infection status.ResultsFour hundred fifty-five (29%) of 1577 participants tested positive for SARS-CoV-2 infection at enrollment; 209 (46%) case-patients and 637 (57%) test-negative patients were NP seropositive, had documented previous laboratory-confirmed COVID-19, or self-reported prior infection. Among previously uninfected patients, three-dose VE was 97% (95% confidence interval [CI], 60%–99%) against Delta, but not statistically significant against Omicron. Among previously infected patients, three-dose VE was 57% (CI, 20%–76%) against Omicron; VE against Delta could not be estimated.ConclusionsThree mRNA COVID-19 vaccine doses provided additional protection against SARS-CoV-2 Omicron variant-associated illness among previously infected participants.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherCOVID-19
dc.subject.otherhybrid immunity
dc.subject.othervaccine effectiveness
dc.titlePrior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 Omicron variant, US Flu VE network
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMicrobiology and Immunology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176890/1/irv13143.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176890/2/irv13143_am.pdf
dc.identifier.doi10.1111/irv.13143
dc.identifier.sourceInfluenza and Other Respiratory Viruses
dc.identifier.citedreferenceKim S, Chung JR, Talbot HK, et al. Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-related outpatient illness among adults, October 2021–February 2022. Influenza Other Respi Viruses. 2022; 1 - 11.
dc.identifier.citedreferenceCromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021; 21 ( 6 ): 395 - 404. doi: 10.1038/s41577-021-00550-x
dc.identifier.citedreferenceGrigoryan L, Pulendran B. The immunology of SARS-CoV-2 infections and vaccines. Semin Immunol. 2020; 50: 101422. doi: 10.1016/j.smim.2020.101422
dc.identifier.citedreferencePost N, Eddy D, Huntley C, et al. Antibody response to SARS-CoV-2 infection in humans: a systematic review. PLoS ONE. 2020; 15 ( 12 ): e0244126. doi: 10.1371/journal.pone.0244126
dc.identifier.citedreferenceShrotri M, van Schalkwyk MCI, Post N, et al. T cell response to SARS-CoV-2 infection in humans: a systematic review. PLoS ONE. 2021; 16 ( 1 ): e0245532. doi: 10.1371/journal.pone.0245532
dc.identifier.citedreferenceWang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021; 592 ( 7855 ): 616 - 622. doi: 10.1038/s41586-021-03324-6
dc.identifier.citedreferenceGoel RR, Apostolidis SA, Painter MM, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. Sci Immunol. 2021; 6 ( 58 ). doi: 10.1126/sciimmunol.abi6950
dc.identifier.citedreferenceShenai MB, Rahme R, Noorchashm H. Equivalency of protection from natural immunity in COVID-19 recovered versus fully vaccinated persons: a systematic review and pooled analysis. Cureus. 2021; 13 ( 10 ): e19102. doi: 10.7759/cureus.19102
dc.identifier.citedreferenceBozio CH, Grannis SJ, Naleway AL, et al. Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity—nine states, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021; 70 ( 44 ): 1539 - 1544. doi: 10.15585/mmwr.mm7044e1
dc.identifier.citedreferenceEbinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021; 27 ( 6 ): 981 - 984. doi: 10.1038/s41591-021-01325-6
dc.identifier.citedreferenceGobbi F, Buonfrate D, Moro L, et al. Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection. Viruses. 2021; 13 ( 3 ): 422. doi: 10.3390/v13030422
dc.identifier.citedreferenceKrammer F, Srivastava K, Alshammary H, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021; 384 ( 14 ): 1372 - 1374. doi: 10.1056/NEJMc2101667
dc.identifier.citedreferenceAltarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of previous infection and vaccination on symptomatic Omicron infections. N Engl J Med. 2022; 387 ( 1 ): 21 - 34. doi: 10.1056/NEJMoa2203965
dc.identifier.citedreferenceKalish H, Klumpp-Thomas C, Hunsberger S, et al. Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States. Sci Transl Med. 2021; 13 ( 601 ). doi: 10.1126/scitranslmed.abh3826
dc.identifier.citedreferenceLi R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020; 368 ( 6490 ): 489 - 493. doi: 10.1126/science.abb3221
dc.identifier.citedreferenceRentsch CT, Kidwai-Khan F, Tate JP, et al. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: a nationwide cohort study. PLoS Med. 2020; 17 ( 9 ): e1003379. doi: 10.1371/journal.pmed.1003379
dc.identifier.citedreferenceSalomon JA, Reinhart A, Bilinski A, et al. The US COVID-19 trends and impact survey: continuous real-time measurement of COVID-19 symptoms, risks, protective behaviors, testing, and vaccination. Proc Natl Acad Sci U S a. 2021; 118 ( 51 ). doi: 10.1073/pnas.2111454118
dc.identifier.citedreferenceRader B, Gertz A, Iuliano AD, et al. Use of at-home COVID-19 tests—United States, August 23, 2021-March 12, 2022. MMWR Morb Mortal Wkly Rep. 2022; 71 ( 13 ): 489 - 494. doi: 10.15585/mmwr.mm7113e1
dc.identifier.citedreferenceChung JR, Kim SS, Jackson ML, et al. Clinical symptoms among ambulatory patients tested for SARS-CoV-2. Open forum. Infect Dis. 2021; 8 ( 1 ): ofaa576. doi: 10.1093/ofid/ofaa576
dc.identifier.citedreferenceTenforde MW, Patel MM, Gaglani M, et al. Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults—United States, August-December 2021. MMWR Morb Mortal Wkly Rep. 2022; 71 ( 4 ): 118 - 124. doi: 10.15585/mmwr.mm7104a2
dc.identifier.citedreferenceAndrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022; 386 ( 16 ): 1532 - 1546. doi: 10.1056/NEJMoa2119451
dc.identifier.citedreferenceChemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nat Commun. 2022; 13 ( 1 ): 3082. doi: 10.1038/s41467-022-30895-3
dc.identifier.citedreferenceTartof SY, Slezak JM, Puzniak L, et al. Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to Omicron and Delta variants. Lancet Respir Med. 2022; 10 ( 7 ): e61 - e62. doi: 10.1016/S2213-2600(22)00170-9
dc.identifier.citedreferenceYu J, Collier AY, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants. N Engl J Med. 2022; 386 ( 16 ): 1579 - 1580. doi: 10.1056/NEJMc2201849
dc.identifier.citedreferenceLiu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022; 602 ( 7898 ): 676 - 681. doi: 10.1038/s41586-021-04388-0
dc.identifier.citedreferenceGudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020; 383 ( 18 ): 1724 - 1734. doi: 10.1056/NEJMoa2026116
dc.identifier.citedreferenceWang H, Yuan Y, Xiao M, et al. Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection. Cell Mol Immunol. 2021; 18 ( 7 ): 1832 - 1834. doi: 10.1038/s41423-021-00708-6
dc.identifier.citedreferenceOrtega N, Ribes M, Vidal M, et al. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nat Commun. 2021; 12 ( 1 ): 4740. doi: 10.1038/s41467-021-24979-9
dc.identifier.citedreferenceFollmann D, Janes HE, Buhule OD, et al. Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 Vaccine Efficacy linical trial. Ann Intern Med. 2022; 175 ( 9 ): 1258 - 1265. doi: 10.7326/M22-1300
dc.identifier.citedreferenceAltarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the Omicron variant from previous SARS-CoV-2 infection. N Engl J Med. 2022; 386 ( 13 ): 1288 - 1290. doi: 10.1056/NEJMc2200133
dc.identifier.citedreferenceAltarawneh HN, Chemaitelly H, Ayoub HH, et al. Protection of SARS-CoV-2 natural infection against reinfection with the Omicron BA.4 or BA.5 subvariants. medRxiv 2022: 2022.07.11.22277448.
dc.identifier.citedreferenceMalato J, Ribeiro RM, Fernandes E, et al. Rapid waning of protection induced by prior BA.1/BA.2 infection against BA.5 infection. medRxiv 2022: 2022.08.16.22278820.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
irv13143.pdf
Size:
882.0KB
Format:
PDF
View/Open
Name:
irv13143_am.pdf
Size:
352.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.